|
- We make healthy possible - Amneal Pharmaceuticals
Amneal Receives U S FDA Approval for Brekiya® (dihydroergotamine mesylate) autoinjector for the Acute Treatment of Migraine and Cluster Headache Episodes See Warning
- Our Story - Amneal Pharmaceuticals
More than two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow’s health challenges
- Careers - Amneal Pharmaceuticals
We believe when our team members grow, Amneal grows Here you are offered meaningful opportunities to build new skills, explore new experiences and share your ideas
- Our Portfolio - Amneal Pharmaceuticals
We are also excited about our work to bring patients more affordable biologic therapy options through our Biosciences, which includes a broad portfolio of institutional injectables as well as Amneal’s growing biosimilars portfolio
- Generic Products - Amneal Pharmaceuticals
View the catalog of Amneal generic products including the epinephrine auto-injector (authorized generic for Adrenaclick)
- Lets Connect - Amneal Pharmaceuticals
Invest@amneal com Corporate Development Inquiries: 400 Crossing Boulevard, 3rd Floor Bridgewater, New Jersey 08807 BusinessDevelopment@amneal com Sales Customer Relations Distribution Sales Operations 118 Beaver Trail Glasgow, Kentucky 42141 CustomerRelations@amneal com Return Goods Policy Authorized Distributors List Government Inquiries
- Our Milestones - Amneal Pharmaceuticals
Amneal has dramatically transformed from its beginnings as a start-up generics company in 2002 to become a highly diversified specialty pharmaceutical company with world-class scientific, production and commercial capabilities
- Research Development - Amneal Pharmaceuticals
A proven track record of innovation for patients The graphic below reflects the timing of when a new product in each dosage form category was initially launched by Amneal or is expected to launch (1) Note: Data as of February 28, 2025 (1) Pipeline includes investigational products not approved by FDA
|
|
|